Vivos Therapeutics (VVOS) Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Operating Expenses data on file, last reported at $9.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 78.26% year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $34.7 million, a 74.36% increase from a year earlier, with the FY2025 full-year figure at $30.4 million, up 50.75% from the prior year.
• Operating Expenses for Q1 2026 stood at $9.7 million, up from $9.4 million in the prior quarter.
• Over the last five years, Operating Expenses for VVOS reached as high as $9.7 million in Q1 2026 and fell as low as $4.6 million in Q2 2024.
• Historically, Operating Expenses has averaged $7.1 million across 5 years, with a median of $7.0 million in 2025.
• Across the five-year window, Operating Expenses tumbled 31.84% in 2023 and jumped 91.11% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $8.4 million in 2022, then retreated by 26.34% to $6.2 million in 2023, then decreased by 21.2% to $4.9 million in 2024, then soared by 91.11% to $9.4 million in 2025, then rose by 3.24% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $9.7 million in Q1 2026, $9.4 million in Q4 2025, and $8.7 million in Q3 2025.